These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

102 related articles for article (PubMed ID: 31282304)

  • 21. Evaluation of an affordable HIV-1 virological failure assay and antiretroviral drug resistance genotyping protocol.
    Bronze M; Aitken SC; Wallis CL; Steegen K; Stuyver LJ; de Wit TF; Stevens W
    J Virol Methods; 2013 Dec; 194(1-2):300-7. PubMed ID: 23994150
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prevalence of HIV drug resistance before and 1 year after treatment initiation in 4 sites in the Malawi antiretroviral treatment program.
    Wadonda-Kabondo N; Bennett D; van Oosterhout JJ; Moyo K; Hosseinipour M; Devos J; Zhou Z; Aberle-Grasse J; Warne TR; Mtika C; Chilima B; Banda R; Pasulani O; Porter C; Phiri S; Jahn A; Kamwendo D; Jordan MR; Kabuluzi S; Chimbwandira F; Kagoli M; Matatiyo B; Demby A; Yang C
    Clin Infect Dis; 2012 May; 54 Suppl 4(Suppl 4):S362-8. PubMed ID: 22544204
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluation of the Zimbabwe HIV case surveillance pilot project, 2019.
    Nsubuga P; Mabaya S; Apollo T; Sithole N; Komtenza B; Matare T; Chimwaza A; Takarinda K; Moyo B; Mbano L; Choto R; Moyo T; Lowrance D; Low-Beer D; Mugurungi O; Gasasira A
    Pan Afr Med J; 2020; 37():353. PubMed ID: 33796167
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Surveillance of transmitted HIV drug resistance among women attending antenatal clinics in Dar es Salaam, Tanzania.
    Somi GR; Kibuka T; Diallo K; Tuhuma T; Bennett DE; Yang C; Kagoma C; Lyamuya EF; Swai RO; Kassim S
    Antivir Ther; 2008; 13 Suppl 2():77-82. PubMed ID: 18575194
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Targeted combination prevention to support female sex workers in Zimbabwe accessing and adhering to antiretrovirals for treatment and prevention of HIV (SAPPH-IRe): a cluster-randomised trial.
    Cowan FM; Davey C; Fearon E; Mushati P; Dirawo J; Chabata S; Cambiano V; Napierala S; Hanisch D; Wong-Gruenwald R; Masuka N; Mabugo T; Hatzold K; Mugurungi O; Busza J; Phillips A; Hargreaves JR
    Lancet HIV; 2018 Aug; 5(8):e417-e426. PubMed ID: 30030134
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Do HIV prevalence trends in antenatal clinic surveillance represent trends in the general population in the antiretroviral therapy era? The case of Manicaland, East Zimbabwe.
    Gregson S; Dharmayat K; Pereboom M; Takaruza A; Mugurungi O; Schur N; Nyamukapa CA
    AIDS; 2015 Sep; 29(14):1845-53. PubMed ID: 26372390
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Predictors of poor retention on antiretroviral therapy as a major HIV drug resistance early warning indicator in Cameroon: results from a nationwide systematic random sampling.
    Billong SC; Fokam J; Penda CI; Amadou S; Kob DS; Billong EJ; Colizzi V; Ndjolo A; Bisseck AZ; Elat JN
    BMC Infect Dis; 2016 Nov; 16(1):678. PubMed ID: 27846809
    [TBL] [Abstract][Full Text] [Related]  

  • 28. HIV drug resistance early warning indicators in cohorts of individuals starting antiretroviral therapy between 2004 and 2009: World Health Organization global report from 50 countries.
    Bennett DE; Jordan MR; Bertagnolio S; Hong SY; Ravasi G; McMahon JH; Saadani A; Kelley KF
    Clin Infect Dis; 2012 May; 54 Suppl 4(Suppl 4):S280-9. PubMed ID: 22544188
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Surveillance of transmitted HIV drug resistance in the Manzini-Mbabane corridor, Swaziland, in 2006.
    Maphalala G; Okello V; Mndzebele S; Gwebu P; Mulima N; Dlamini S; Nhlabatsi B; Ginindza T; Ghebrenegus Y; Ntilivamunda A; Mwanyumba F; Ledwaba J; Pillay V; Bennett DE
    Antivir Ther; 2008; 13 Suppl 2():95-100. PubMed ID: 18575197
    [TBL] [Abstract][Full Text] [Related]  

  • 30. HIV drug resistance threshold survey using specimens from voluntary counselling and testing sites in Hanoi, Vietnam.
    Nguyen HT; Duc NB; Shrivastava R; Tran TH; Nguyen TA; Thang PH; McNicholl JM; Leelawiwat W; Chonwattana W; Sidibe K; Fujita M; Luu CM; Kakkar R; Bennett DE; Kaplan J; Cosimi L; Wolfe MI
    Antivir Ther; 2008; 13 Suppl 2():115-21. PubMed ID: 18575200
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Reductions in virological failure and drug resistance in Chinese antiretroviral-treated patients due to lamivudine-based regimens, 2003-12.
    Xing H; Ruan Y; Hsi JH; Kan W; Liao L; Leng X; Wang J; He C; Shao Y;
    J Antimicrob Chemother; 2015 Jul; 70(7):2097-103. PubMed ID: 25855758
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Transmission of drug resistant HIV and its potential impact on mortality and treatment outcomes in resource-limited settings.
    Cambiano V; Bertagnolio S; Jordan MR; Lundgren JD; Phillips A
    J Infect Dis; 2013 Jun; 207 Suppl 2():S57-62. PubMed ID: 23687290
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Antiretroviral treatment sequencing strategies to overcome HIV type 1 drug resistance in adolescents and adults in low-middle-income countries.
    De Luca A; Hamers RL; Schapiro JM
    J Infect Dis; 2013 Jun; 207 Suppl 2():S63-9. PubMed ID: 23687291
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Surveillance of transmitted HIV drug resistance with the World Health Organization threshold survey method in Lilongwe, Malawi.
    Kamoto K; Aberle-Grasse J;
    Antivir Ther; 2008; 13 Suppl 2():83-7. PubMed ID: 18575195
    [TBL] [Abstract][Full Text] [Related]  

  • 35. World Health Organization/HIVResNet Drug Resistance Laboratory Strategy.
    Bertagnolio S; Derdelinckx I; Parker M; Fitzgibbon J; Fleury H; Peeters M; Schuurman R; Pillay D; Morris L; Tanuri A; Gershy-Damet GM; Nkengasong J; Gilks CF; Sutherland D; Sandstrom P
    Antivir Ther; 2008; 13 Suppl 2():49-57. PubMed ID: 18575191
    [TBL] [Abstract][Full Text] [Related]  

  • 36. HIV drug resistance transmission threshold survey in Bangkok, Thailand.
    Sirivichayakul S; Phanuphak P; Pankam T; O-Charoen R; Sutherland D; Ruxrungtham K
    Antivir Ther; 2008; 13 Suppl 2():109-13. PubMed ID: 18575199
    [TBL] [Abstract][Full Text] [Related]  

  • 37. HIV Drug Resistance Among Children Initiating First-Line Antiretroviral Treatment in Uganda.
    Kityo C; Sigaloff KC; Sonia Boender T; Kaudha E; Kayiwa J; Musiime V; Mukuye A; Kiconco M; Nankya I; Nakatudde-Katumba L; Calis JC; Rinke de Wit TF; Mugyenyi PN
    AIDS Res Hum Retroviruses; 2016 Jul; 32(7):628-35. PubMed ID: 26723018
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Challenges to and opportunities for the adoption and routine use of early warning indicators to monitor pediatric HIV drug resistance in Kenya.
    Pilgrim NA; Okal J; Matheka J; Mukui I; Kalibala S
    BMC Pediatr; 2018 Jul; 18(1):243. PubMed ID: 30045700
    [TBL] [Abstract][Full Text] [Related]  

  • 39. HIV drug resistance early warning indicators in namibia with updated World Health Organization guidance.
    Jonas A; Sumbi V; Mwinga S; DeKlerk M; Tjituka F; Penney S; Jordan MR; Desta T; Tang AM; Hong SY
    PLoS One; 2014; 9(7):e100539. PubMed ID: 24988387
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Update on World Health Organization HIV drug resistance prevention and assessment strategy: 2004-2011.
    Jordan MR; Bennett DE; Wainberg MA; Havlir D; Hammer S; Yang C; Morris L; Peeters M; Wensing AM; Parkin N; Nachega JB; Phillips A; De Luca A; Geng E; Calmy A; Raizes E; Sandstrom P; Archibald CP; Perriëns J; McClure CM; Hong SY; McMahon JH; Dedes N; Sutherland D; Bertagnolio S
    Clin Infect Dis; 2012 May; 54 Suppl 4(Suppl 4):S245-9. PubMed ID: 22544182
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.